

Monoclonal Antibody Therapy



The delta variant is increasing COVID-19 cases, resulting in serious illness, hospitalizations and deaths.

Monoclonal antibody (mAb) therapies can help prevent severe illness, save lives, and reduce the burden on our hospitals and health systems.

This therapy is now available through shots, making it easier to get.

Why get mAb therapy?



- It can reduce hospitalization by up to 70% for COVID-positive people with currently mild to moderate symptoms.
- It reduces the risk of getting COVID-19 by up to 81%, if a person gets treated after exposure.
- It reduces risk of death.
- It is proven effective against the Delta variant.

What are monoclonal antibodies?



Monoclonal antibodies (mAbs) are antibodies developed in a lab that block the virus from entering your cells.

Who is eligible for mAb therapy?

Individuals 12 and older who weighs at least 88 pounds (40 kg) who:

1. Have tested positive for COVID-19

- Are within 10 days of having symptoms
- Have mild to moderate symptoms
- Are outpatients and not on oxygen therapy
- And are considered [high risk patients](#).

2. Have been exposed to COVID-19 or are at high risk of exposure

due to cases in an institutional setting (like nursing homes) AND are not completely vaccinated AND are considered [high risk](#). Fully vaccinated people are also considered eligible in certain situations.



How can I get mAb therapy?

Contact your health care provider to learn more and find out if you are eligible for this treatment.

